
Soleno Therapeutics Goes Private in All-Cash Merger, Dissolving Board and Delisting from Nasdaq
Soleno Therapeutics, Inc.Description
What this story covers
Soleno Therapeutics completed a total transformation into a private subsidiary via an all-cash merger. This involved the entire board and executive team resigning, debt termination, and a full delisting from Nasdaq.
Story snapshot
CompanySoleno Therapeutics, Inc.
TickerSLNO
VariantStandard detailed
Duration4:46
Filing type8-K
PeriodAnnual 2026
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-228016
Sources1
Full Story Script
Content not available for this story.